• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Corcept Therapeutics

Corcept Therapeutics

Corcept Therapeutics Inc CORT

Last Price$4.83Day Change (%)-3.40%
Open Price$4.90Day Change ($)-0.17
Day Range4.77–4.9552-Week Range2.59–7.67

As of Tue 9/1/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering

    Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering

  2. Cortendo Announces Plans to Redomicile the Cortendo Group’s Parent Company from Sweden to Ireland By Means of an Exchange Offer

    Cortendo Announces Plans to Redomicile the Cortendo Group’s Parent Company from Sweden to Ireland By Means of an Exchange Offer

  3. A Young Power Couple's Kickstart Portfolio

    With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.

  4. Even in Face of Difficulty, Berkshire Impresses

    Berkshire's non-insurance operations continue to be an added source of stability while reinsurance operations continue to struggle.

  5. Investment Losses Overshadow Berkshire's Third-Quarter Results

    Wide-moat Berkshire Hathaway saw solid top-line results from each of its main segments, but losses from investments, derivatives, and eliminations sent earnings lower.

  6. Berkshire's Second-Quarter Results on Target

    Noninsurance operations continue to be a source of stability, while its insurance business overall may see more meager results during the next couple of years.

  7. Berkshire Starts Out 2014 on a Weaker Note

    Just about every segment at Berkshire was dealing with elevated costs during the first quarter.

  8. Why Berkshire's Moat Isn't Going Away Anytime Soon

    Morningstar's Gregg Warren says Berkshire's sterling balance sheet, strong business, and unique structure will sustain the firm's competitive standing--even without Buffett.

  9. How We Value Berkshire Hathaway

    Alternative methods have some use, but we think discounted cash flow is the most fundamentally sound way to value the conglomerate, as we discuss in the final installment of our 5-part series.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.